Last September the Financial Conduct Authority determined that UK-based medicinal cannabis companies could list their shares publicly – partially clearing up a grey area around this issue. Grow Group is planning to be one of the first of a new wave of companies bringing relief to those suffering the effects of cancer, chronic pain, sickness or severe epilepsy whose only recourse for relief to date has been the black market. Below, we speak with Ben Langley, Grow’s chief executive, about the company's plans. Grow Group is grappling with the task of creating a supply chain for medicinal cannabis Okay, this example is a little ‘old economy’, but bear with me here, there is a broader point. Imagine, if you will, setting up a greengrocer shop.